Additionally, it has been demonstrated that CXCR4 inhibitors (AMD3100 and YN14003) can significantly mitigate tumor progression in HER2 overexpressing breast tumor models thereby indicating that CXCR4 attenuation could be a useful strategy for targeting HER2 breast cancer patients [26]. The gene discussed is CXCR4; the disease is breast carcinoma.